Product details:

ISBN13:9789819969982
ISBN10:98199699811
Binding:Hardback
No. of pages:449 pages
Size:235x155 mm
Weight:869 g
Language:English
Illustrations: 2 Illustrations, black & white; 34 Illustrations, color
674
Category:

Challenges and Solutions Against Visceral Leishmaniasis

 
Edition number: 1st ed. 2023
Publisher: Springer
Date of Publication:
Number of Volumes: 1 pieces, Book
 
Normal price:

Publisher's listprice:
EUR 192.59
Estimated price in HUF:
79 472 HUF (75 687 HUF + 5% VAT)
Why estimated?
 
Your price:

63 577 (60 550 HUF + 5% VAT )
discount is: 20% (approx 15 894 HUF off)
Discount is valid until: 30 June 2024
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
 
Availability:

Not yet published.
 
  Piece(s)

 
Short description:

This book comprehensively reviews the epidemiology and surveillance strategies of Visceral Leishmaniasis, and the latest developments in disease diagnosis, drug discovery, and vaccine development. The initial chapters cover the epidemiology features and spatial distribution of Visceral Leishmaniasis. The book further discusses the manifestations of HIV-Visceral Leishmaniasis infection on the immunopathogenesis, diagnosis, and therapeutic response. It analyzes the role of different proteomic technologies in understanding the parasite development, survival, drug resistance mechanisms, host-pathogen interactions, and the development of new therapeutic approaches. The book concludes by discussing recent advancements in vaccine development for Visceral Leishmaniasis. It discusses the promising vaccine candidate, their developmental status, current challenges, and prospects for rational vaccine development against Leishmania. This book is an invaluable source of information for students, and researchers working to understand the Leishmania biology, and drug development.

Long description:

This book comprehensively reviews the epidemiology and surveillance strategies of Visceral Leishmaniasis, and the latest developments in disease diagnosis, drug discovery, and vaccine development. The initial chapters cover the epidemiology features and spatial distribution of Visceral Leishmaniasis. The book further discusses the manifestations of HIV-Visceral Leishmaniasis infection on the immunopathogenesis, diagnosis, and therapeutic response. It analyzes the role of different proteomic technologies in understanding the parasite development, survival, drug resistance mechanisms, host-pathogen interactions, and the development of new therapeutic approaches. The book concludes by discussing recent advancements in vaccine development for Visceral Leishmaniasis. It discusses the promising vaccine candidate, their developmental status, current challenges, and prospects for rational vaccine development against Leishmania. This book is an invaluable source of information for students, and researchers working to understand the Leishmania biology, and drug development.

Table of Contents:

Chapter 1_KalaCORE ? a programme to tackle Visceral Leishmaniasis in East Africa. -Chapter 2_Spatio-temporal variation in Kala-azar intensity and sand fly density: role of local climate in highlighting the disease transmission in Bihar, India. -Chapter 3_Visceral leishmaniasis and HIV co-infection: double trouble. -Chapter 4_Leishmania-Leptomonas co-infection scenario in India and possibilities. -Chapter 5_Post kala-azar dermal leishmaniasis (PKDL)-challenges in the diagnosis and treatment. -Chapter 6_Leishmania infection on global host proteome: Impact for marker development and treatment. - Chapter 7_Leishmania proteomics:  an insight into diagnostics and vaccine development. - Chapter 8_Emergence of novel L. donovani variants: A new challenge to the ongoing Leishmaniasis Elimination program. - Chapter 9_Atypical leishmaniasis in Sri Lanka: A challenge to disease elimination. - Chapter 10_Heat shock proteins of Leishmania: an emerging therapeutic and vaccine targets. -Chapter 11_Advances in Antileishmanial Chemotherapy. - Chapter 12_Miltefosine unresponsiveness in visceral leishmaniasis. - Chapter 13_Drugs for Visceral leishmaniasis ?perspectives for treatment, prevention and control. - Chapter 14_Pre-clinical models for the vaccine/drug research against VL. - Chapter 15_Towards a Safe and Efficacious pan Leishmania Vaccine. - Chapter 16_Understanding the heterogeneity in Mast Cell role in host defense during Leishmaniasis. - Chapter 17_Feasibility of therapeutic vaccine for the management and control of VL. - Chapter 18_Prevention of Visceral Leishmaniasis using vaccination:  A review of the worldwide efforts.



?